ArticleJournal of cheminformatics2024
cidalsDB: an AI-empowered platform for anti-pathogen therapeutics research.
Article in Journal of cheminformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Towards precision antileishmanial drug discovery: Integrating multi-omics, functional genomics, artificial intelligence and host-directed therapeutics.Molecular biology reports · 2026Review
- Molecular docking: a computational approach for the discovery of novel targets against visceral leishmaniasis.Journal of molecular modeling · 2026Review
- Article
- Adjusted imbalance ratio leads to effective AI-based drug discovery against infectious disease.Scientific reports · 2025Article
- Tranylcypromine: a promising repurposed drug against Leishmaniases.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Computer-aided drug discovery (CADD) is nurtured by late advances in big data analytics and Artificial Intelligence (AI) towards enhanced drug discovery (DD) outcomes. In this context, reliable datasets are of utmost importance. We herein present CidalsDB a novel web server for AI-assisted DD against infectious pathogens, namely Leishmania parasites and Coronaviruses. We performed a literature search on molecules with validated anti-pathogen effects. Then, we consolidated these data with bioassays from PubChem. Finally, we constructed a database to store these datasets and make them accessible and ready-to-use for the scientific community through CidalsDB, a web-based interface. In a second step, we implemented and optimized four machine learning (ML) and three deep learning (DL) algorithms that optimally predicted the biological activity of molecules. Random Forests (RF), Multi-Layer Perceptron (MLP) and ChemBERTa were the best classifiers of anti-Leishmania molecules, while Gradient Boosting (GB), Graph-Convolutional Network (GCN) and ChemBERTa achieved the best performances on the Coronaviruses dataset. All six models were optimized and deployed through CidalsDB as anti-pathogen activity prediction models.Scientific contributionCidalsDB is an open access web-based tool that allows browsing and access to ready-to-use datasets of anti-pathogen molecules, alongside best performing AI models for biological activity prediction. It offers a democratized no-code platform for AI-based CADD, which shall foster innovation and collaboration within the DD community. CidalsDB is accessible through https://cidalsdb.streamlit.app/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.